Similar articles for PMID: 18505052

Year	Number of Results
1992	1
1993	1
2001	1
2002	2
2003	3
2004	1
2005	9
2006	7
2007	7
2008	19
2009	26
2010	3
2011	3
2012	1
2013	4
2014	3
2019	2
2022	1
2024	0

1

Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.

Sève P, Reiman T, Isaac S, Trillet-Lenoir V, Lafanéchère L, Sawyer M, Dumontet C. Sève P, et al. Anticancer Res. 2008 Mar-Apr;28(2B):1161-7. Anticancer Res. 2008. PMID: 18505052 Free article.

2

Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.

Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR. Sève P, et al. Cancer Chemother Pharmacol. 2007 Jun;60(1):27-34. doi: 10.1007/s00280-006-0343-1. Epub 2006 Sep 22. Cancer Chemother Pharmacol. 2007. PMID: 17021819 Clinical Trial.

3

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller EL, Dumontet C. Sève P, et al. Clin Cancer Res. 2005 Aug 1;11(15):5481-6. doi: 10.1158/1078-0432.CCR-05-0285. Clin Cancer Res. 2005. PMID: 16061864

4

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H. Azuma K, et al. Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1. Lung Cancer. 2009. PMID: 18977553

5

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C. Leskelä S, et al. Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb. Endocr Relat Cancer. 2010. PMID: 21051560

6

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.

Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Su D, et al. Cancer. 2009 Jun 1;115(11):2453-63. doi: 10.1002/cncr.24282. Cancer. 2009. PMID: 19322891 Free article.

7

Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.

Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, Kikkawa F. Umezu T, et al. Int J Gynecol Pathol. 2008 Apr;27(2):207-12. doi: 10.1097/PGP.0b013e318156c838. Int J Gynecol Pathol. 2008. PMID: 18317222

8

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial.

9

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y. Okuda K, et al. Lung Cancer. 2008 Oct;62(1):105-12. doi: 10.1016/j.lungcan.2008.02.021. Epub 2008 Apr 18. Lung Cancer. 2008. PMID: 18395930

10

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G. Mozzetti S, et al. Clin Cancer Res. 2005 Jan 1;11(1):298-305. Clin Cancer Res. 2005. PMID: 15671559

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

82 results

Results by year